Immuron Management

Management criteria checks 1/4

Immuron's CEO is Steve Lydeamore, appointed in Jun 2022, has a tenure of 4.25 years. total yearly compensation is A$738.37K, comprised of 61.7% salary and 38.3% bonuses, including company stock and options. directly owns 0.98% of the company’s shares, worth €85.78K. The average tenure of the management team and the board of directors is 0.6 years and 7 years respectively.

Key information

Steve Lydeamore

Chief executive officer

AU$738.4k

Total compensation

CEO salary percentage	61.67%
CEO tenure	4.3yrs
CEO ownership	1.0%
Management average tenure	less than a year
Board average tenure	7yrs

Recent management updates

Recent updates

CEO Compensation Analysis

How has Steve Lydeamore's remuneration changed compared to Immuron's earnings?
Date	Total Compensation	Salary	Company Earnings
Jun 30 2026	n/a	n/a	-AU$4m
Mar 31 2026	n/a	n/a	-AU$4m
Dec 31 2025	n/a	n/a	-AU$5m
Sep 30 2025	n/a	n/a	-AU$5m
Jun 30 2025	AU$738k	AU$455k	-AU$5m
Mar 31 2025	n/a	n/a	-AU$6m
Dec 31 2024	n/a	n/a	-AU$7m
Sep 30 2024	n/a	n/a	-AU$7m
Jun 30 2024	AU$599k	AU$436k	-AU$7m
Mar 31 2024	n/a	n/a	-AU$5m
Dec 31 2023	n/a	n/a	-AU$4m
Sep 30 2023	n/a	n/a	-AU$4m
Jun 30 2023	AU$584k	AU$415k	-AU$4m
Mar 31 2023	n/a	n/a	-AU$3m
Dec 31 2022	n/a	n/a	-AU$3m
Sep 30 2022	n/a	n/a	-AU$3m
Jun 30 2022	AU$781k	AU$6k	-AU$3m

Compensation vs Market: Steve's total compensation ($USD526.54K) is above average for companies of similar size in the German market ($USD396.26K).

Compensation vs Earnings: Steve's compensation has increased whilst the company is unprofitable.

CEO

Steve Lydeamore (58 yo)

4.3yrs

Tenure

AU$738,372

Compensation

Mr. Steven George Lydeamore, also known as Steve, MBA, CPA, serves as Chief Executive Officer at Immuron Limited since June 27, 2022. He served as the Chief Executive Officer of Anatara Lifesciences Limite...

Leadership Team

Name	Position	Tenure	Compensation	Ownership
Steven Lydeamore	Chief Executive Officer	4.3yrs	AU$738.37k	0.98% € 85.8k
Jerry Kanellos	Chief Scientific Officer	less than a year	AU$384.59k	0.10% € 9.1k
Flavio Palumbo	Chief Commercial Officer	3.8yrs	AU$387.65k	0.35% € 31.1k
Aaron Laurita	Chief Financial Officer	less than a year	no data	no data
David Lyon	Head of Marketing	no data	no data	no data
Olga Smejkalova	Company Secretary	less than a year	no data	no data

0.6yrs

Average Tenure

58yo

Average Age

Experienced Management: ANW's management team is not considered experienced ( 0.6 years average tenure), which suggests a new team.

Board Members

Name	Position	Tenure	Compensation	Ownership
Glenn Tillotson	Member of Advisory Board	no data	no data	no data
Jeannette Joughin	Independent Non-Executive Director	2.3yrs	AU$106.43k	no data
Daniel Pollock	Independent Non-Executive Director	13.9yrs	AU$145.70k	0.23% € 20.2k
Paul Brennan	Independent Non-Executive Chairman	4.5yrs	AU$176.42k	no data
Dena Lyras	Member of Advisory Board	no data	no data	no data
Ravi Savarirayan	Independent Non-Executive Director	9.4yrs	AU$92.48k	0.27% € 23.9k
Sahil Khanna	Member of Advisory Board	no data	no data	no data
Paul Feuerstadt	Member of Advisory Board	no data	no data	no data
Teena Chopra	Member of Advisory Board	no data	no data	no data

7.0yrs

Average Tenure

63yo

Average Age

Experienced Board: ANW's board of directors are considered experienced (7 years average tenure).

Company Analysis and Financial Data Status

Data	Last Updated (UTC time)
Company Analysis	2026/09/15 03:19
End of Day Share Price	2026/09/15 00:00
Earnings	2026/06/30
Annual Earnings	2026/06/30

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

Package	Data	Timeframe	Example US Source ^*
Company Financials	10 years	Income statement Cash flow statement Balance sheet	SEC Form 10-K SEC Form 10-Q
Analyst Consensus Estimates	+3 years	Forecast financials Analyst price targets	Analyst Research Reports Blue Matrix
Market Prices	30 years	Stock prices Dividends, Splits and Actions	ICE Market Data SEC Form S-1
Ownership	10 years	Top shareholders Insider trading	SEC Form 4 SEC Form 13D
Management	10 years	Leadership team Board of directors	SEC Form 10-K SEC Form DEF 14A
Key Developments	10 years	Company announcements	SEC Form 8-K

^* Example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.

Analyst Sources

Immuron Limited is covered by 2 analysts. 1 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

Analyst	Institution
Karen Sterling	Emerging Growth Research LLC
Raghuram Selvaraju	H.C. Wainwright & Co.

Immuron Management

Management criteria checks 1/4

Key information

Recent management updates

Immuron Limited, Annual General Meeting, Nov 11, 2025

Immuron Limited, Annual General Meeting, Nov 18, 2024

Immuron Limited Appoints Jeannette Joughin as Director

Immuron Limited Announces Resignation of Roger Aston as Non-Executive Director

Immuron Limited, Annual General Meeting, Nov 21, 2023

Insufficient new directors

Recent updates

Full year 2026 earnings released: AU$0.013 loss per share (vs AU$0.023 loss in FY 2025)

Immuron Advances Imm-529 Partnering Strategy and Provides Updates on Clinical Development

Immuron Limited has filed a Follow-on Equity Offering in the amount of AUD 3.596835 million.

Immuron Limited has completed a Follow-on Equity Offering in the amount of AUD 0.642228 million.

Immuron Limited has filed a Follow-on Equity Offering in the amount of AUD 0.642228 million.

Immuron Limited Announces Clinical Trial Update

Immuron Limited has completed a Follow-on Equity Offering in the amount of AUD 0.100458 million.

Immuron Limited has filed a Follow-on Equity Offering in the amount of AUD 0.100458 million.

Immuron Limited, Annual General Meeting, Nov 11, 2025

Immuron Limited has completed a Follow-on Equity Offering in the amount of AUD 2.711754 million.

Immuron Limited has completed a Follow-on Equity Offering in the amount of AUD 0.034072 million.

Immuron Limited has completed a Follow-on Equity Offering in the amount of AUD 0.063351 million.

Immuron Limited has filed a Follow-on Equity Offering in the amount of AUD 0.063351 million.

Immuron Limited has completed a Follow-on Equity Offering in the amount of AUD 0.008261 million.

Immuron Limited has completed a Follow-on Equity Offering in the amount of AUD 0.009723 million.

Immuron Limited has filed a Follow-on Equity Offering in the amount of AUD 0.152602 million.

Immuron Announces Travelan Clinical Trial Update

Immuron Limited has completed a Follow-on Equity Offering in the amount of AUD 0.225471 million.

Immuron Limited has filed a Follow-on Equity Offering in the amount of AUD 0.225471 million.

Immuron Limited, Annual General Meeting, Nov 18, 2024

Immuron Limited Announces NMRC Reports Results for Campylobacter Clinical Study

Full year 2024 earnings released: AU$0.03 loss per share (vs AU$0.017 loss in FY 2023)

Full year 2024 earnings released: AU$0.03 loss per share (vs AU$0.017 loss in FY 2023)

Immuron Limited has filed a Follow-on Equity Offering in the amount of $2.069083 million.

Immuron Requests Pre-IND Meeting for IMM-529 with FDA Filing

Immuron Limited Appoints Jeannette Joughin as Director

Immuron Limited Announces Resignation of Roger Aston as Non-Executive Director

Immuron Limited Announces Positive Results Support Travelan Progress to Phase 3 Clinical Trials in the US

Immuron Limited Clinical Trials Update

Immuron Announces First Patients Enrolled in Campylobacter Challenge Clinical Study

Immuron Limited, Annual General Meeting, Nov 21, 2023

Immuron Limited Announces Travelan® Clinical Study Cohort 2 Commences

Full year 2023 earnings released: AU$0.017 loss per share (vs AU$0.013 loss in FY 2022)

Full year 2023 earnings released: AU$0.017 loss per share (vs AU$0.013 loss in FY 2022)

Immuron Limited Announces First Patients Enrolled in Travelan® Clinical Study

Immuron Limited Initiates Recruitment of Travelan Clinical Study

Immuron Limited Announces US Food and Drug Administration Removed Clinical Hold on New Campylobacter ETEC Therapeutic Paves Way for Clinical Trial Initiation

First half 2023 earnings released: AU$0.009 loss per share (vs AU$0.008 loss in 1H 2022)

Immuron US DoD Naval Medical Research Center Responds to FDA Clinical Hold for New Campylobacter ETEC Therapeutic

Insufficient new directors

Full year 2022 earnings released: AU$0.012 loss per share (vs AU$0.038 loss in FY 2021)

Insufficient new directors

First half 2022 earnings: Revenues and EPS in line with analyst expectations

Full year 2021 earnings released: AU$0.038 loss per share (vs AU$0.017 loss in FY 2020)

Executive Vice Chairman Peter Anastasiou has left the company

Insufficient new directors

First half 2021 earnings released: AU$0.026 loss per share (vs AU$0.009 loss in 1H 2020)

CEO Compensation Analysis

CEO

Leadership Team

Board Members

Company Analysis and Financial Data Status

Data Sources

Analysis Model and Snowflake

Industry and Sector Metrics

Analyst Sources